Ionis Pharmaceuticals 주식 (NASDAQ: IONS)

에 대한 최신 뉴스 Ionis Pharmaceuticals (NASDAQ:IONS) 주식

Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals Inc

Barclays analyst David Anderson reinstates National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) with a Overweight and announces $16 price target.

News

Price Target

Initiation

Analyst Ratings

NESR

Barclays Reinstates Overweight on National Energy Services, Announces $16 Price Target

JP Morgan analyst Cory Carpenter initiates coverage on ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Overweight rating and announces Price Target of $55.

JP Morgan Initiates Coverage On ODDITY Tech with Overweight Rating, Announces Price Target of $55

In the first quarter of 2025, earnings are expected to remain weak due to delayed entry into the flagship system-on-a-chip (SoC) market. However, demand for core products such as image sensors and DDI is expected to increase on the back of flagship smartphone launches.
Looking ahead to the first quarter of 2025, earnings are expected to remain weak due to sluggish mobile demand and fixed-cost burden stemming from lower utilization rates.
 &nbsp;

Guidance

SSNLF

Reported Earlier, Samsung Expects Overall Memory Market Demand To Recover From Q2; Expects Earnings To Remain Weak In Q1

JP Morgan analyst Jeffrey Zekauskas upgrades Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) from Neutral to Overweight and lowers the price target from $210 to $205.

Upgrades

JP Morgan Upgrades Avery Dennison to Overweight, Lowers Price Target to $205

Baird analyst Benjamin Hartford downgrades United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) from Outperform to Neutral and lowers the price target from $160 to $130.

Downgrades

Baird Downgrades United Parcel Service to Neutral, Lowers Price Target to $130

The Company posted KRW 75.8 trillion in consolidated revenue and KRW 6.5 trillion in operating profit in the quarter ended December 31, 2024. For the full year, it reported KRW 300.9 trillion in annual revenue and KRW 32.7 trillion in operating profit.
 &nbsp;

Earnings

Reported Earlier, Samsung Electronics Says Q1 Overall Earnings Improvement May Be Limited Due To Weakness In Semiconductors Business

Jefferies analyst Christopher LeFemina initiates coverage on Core Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNR#NYSE">CNR</a>) with a Hold rating and announces Price Target of $93.

Jefferies Initiates Coverage On Core Natural Resources with Hold Rating, Announces Price Target of $93

Canaccord Genuity analyst Sumant Kulkarni downgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Buy to Hold and raises the price target from $119 to $132.

ITCI

Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold, Raises Price Target to $132

Global payment technology companies, Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) and Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), which process credit card payments and other financial transactions reported better-than-expected quarterly earnings on Thursday. Shall investors buy, sell or hold these companies? Here&#8217;s what technical analysis suggests.
<h3 class="wp-block-heading">Technical Analysis Of Visa And Mastercard</h3>
Technical analysis suggests both Visa and Mastercard stocks are currently overbought, indicating a potential correction may be imminent, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
Visa shares closed Thursday at $343.05, significantly above its eight-day simple moving average of $331.69, 20-day average at $320.65, also 50 and 200-day averages of $316.42, and $285.73, respectively. The relative strength index of 80.35 further reinforces this overbought condition, suggesting recent rapid price increases may be unsustainable.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-1024x576.png" alt="" class="wp-image-759794" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043122/VISA-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/news/earnings/25/01/43355517/visa-shares-rise-on-solid-q1-results-details">Visa Shares Rise On Solid Q1 Results: Details</a> 
Mastercard shares, on the other hand, also exhibited a similar trend, closing Thursday at $566.01. This price is well above its eight-day average of $541.60, and 20-day average of $526.54. Also, 50 and 200-day averages of $526.67 and $484.31, respectively. With an RSI of 76.67, Mastercard&#8217;s stock is also considered overbought, signaling potential exhaustion of upward momentum and a possible sell signal.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-1024x576.png" alt="" class="wp-image-759795" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043127/Mastercard-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/news/earnings/25/01/43345282/mastercard-q4-earnings-revenue-and-eps-beat-strong-growth-in-payments-and-cross-border-transactions">Mastercard Q4 Earnings: Revenue And EPS Beat, Strong Growth In Payments and Cross-Border Transactions</a>
<h3 class="wp-block-heading">Analyst Recommendations</h3>
Despite the warning signs from the technical analysis of daily moving averages, ratings based on analysts tracked by Benzinga have a consensus &#8216;buy&#8217; on both stocks.
Visa also enjoys a consensus &#8220;buy&#8221; rating. The average price target among <a href="https://www.benzinga.com/quote/V/analyst-ratings">34 analysts</a> is $324.06, with a range of $252 to $375. Recent ratings from Piper Sandler, BofA Securities, and Citigroup suggest a $351 target, implying a 0.90% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/V/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="379" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-1024x379.png" alt="" class="wp-image-759801" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-1024x379.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-300x111.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1-768x284.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043240/Visa-ANR-1.png 1062w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/25/01/43376448/elon-musks-x-money-to-see-about-600-million-active-monthly-users-via-visa-direct-integration">Elon Musk&#8217;s &#8216;X Money&#8217; To See About 600 Million Active Monthly Users Via Visa Direct Integration: &#8216;Excited To Partner,&#8217; Says CEO</a>
For Mastercard, the average price target among <a href="https://www.benzinga.com/quote/MA/analyst-ratings">34 analysts</a> is $542.84, with estimates ranging from $424 to $654. Recent ratings from Piper Sandler, Citigroup, and Oppenheimer suggest a $587.67 target, implying a potential upside of 3.53%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="386" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-1024x386.png" alt="" class="wp-image-759797" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-1024x386.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1-768x290.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/31043146/Mastercard-ANR-1.png 1060w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Price Action: Shares of Visa were up 1.41% and Mastercard advanced 0.29% in premarket on Friday. Whereas the exchange-traded fund tracking S&amp;P 500, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.49% at $608.01.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43377987/after-imposing-tariffs-on-canada-donald-trump-threatens-100-levy-on-brics-for-move-against-dollar-how-will-us-manage-production-from-slippers-to-ships-asks-expert">After Imposing Tariffs On Canada, Donald Trump Threatens 100% Levy On BRICS For Move Against Dollar: &#8216;How Will US Manage Production From Slippers To Ships?,&#8217; Asks Expert</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Market Summary

Futures

Technicals

Markets

Trading Ideas

General

Mastercard Vs. Visa: Buy, Sell Or Hold? Here's What Technical Analysis Suggest

Qudian Announced Appointment Of Marcum Asia CPAs As Company's New Independent Registered Public Accounting Firm

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Neutral&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the Dow Jones index gaining more than 150 points as investors assessed the recent earnings reports from mega-cap tech stocks.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reported weaker-than-expected fourth-quarter earnings and sales results. The company, meanwhile, said it expects its vehicle business to return to growth in 2025. Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported better-than-expected fourth-quarter sales results on Wednesday. Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported its second-quarter GAAP earnings of $3.23 per share, beating the $3.11 consensus estimate.
President Donald Trump confirmed Thursday the United States will impose 25% tariffs on imports from Canada and Mexico starting Saturday, Feb. 1.
On the economic data front, U.S. initial jobless claims fell by 16,000 from the previous week to 207,000 in the week ending January 25, compared to market estimates of 220,000. The U.S. economy expanded at an annualized rate of 2.3% in the fourth quarter, down from 3.1% in the previous quarter and versus market estimates of 2.6%.
Most sectors on the S&amp;P 500 closed on a positive note, with utilities, real estate and health care stocks recording gains on Thursday. However, information technology stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 169 points to 44,882.13 on Thursday. The S&amp;P 500 rose 0.53% to 6,071.17, while the Nasdaq Composite rose 0.25% at 19,681.75 during Thursday's session.
Investors are awaiting earnings results from Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) today.
At a current reading of 48.1, the index remained in the &#8220;Neutral&#8221; zone on Thursday, versus a prior reading of 46.5.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43336168/jim-cramer-likes-this-tech-stock-terrific-business-niche-business">Jim Cramer Likes This Tech Stock: &#8216;Terrific Business, Niche Business&#8217;</a></li>
</ul>

Pre-Market Outlook

MSFT

Dow Jumps Over 150 Points As Investors Monitor Earnings Reports; Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone

Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose sharply in today's pre-market trading after the company reported <a href="https://in.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">better-than-expected first-quarter results.</a>
Apple reported fiscal first-quarter revenue of $124.3 billion, beating analyst estimates of $124.13 billion. The iPhone maker reported first-quarter adjusted earnings of $2.40 per share, beating analyst estimates of $2.36 per share.
Apple shares gained 3.4% to $245.73 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Trident Digital Tech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) gained 104% to $1.94 in pre-market trading after dipping 62% on Thursday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) rose 63.4% to $2.55 in pre-market trading after announcing a partnership to advance subsea autonomy solutions.</li>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) gained 40% to $49.01 in pre-market trading after dipping 30% on Thursday.</li>
<li>Orangekloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) gained 37.2% to $1.88 in pre-market trading. Maxim Group analyst Allen Klee initiated coverage on Orangekloud Technology with a Buy rating and announced a price target of $5.</li>
<li>Cyclerion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) rose 25.1% to $3.18 in pre-market trading after gaining 7% on Thursday.</li>
<li>Envirotech Vehicles, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) shares jumped 17.7% to $0.4077 in pre-market trading after dipping 48% on Thursday. Envirotech Vehicles recently announced it has received orders for 48 vehicles to New Jersey.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) gained 20.9% to $5.68 in pre-market trading after the company announced a $50 million investment from Softbank.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) rose 18.9% to $317.40 in pre-market trading after the company reported better-than-expected second-quarter financial results.</li>
<li>Kimball Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) gained 11% to $20.11 in pre-market trading. Kimball Electronics will report second quarter fiscal year 2025 financial results on Tuesday, Feb. 4, 2025, after the closing bell.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aviat Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) shares fell 46.5% to $10.00 in pre-market trading. Aviat Networks will release its second quarter fiscal 2025 financial results for the period ended Dec. 27, 2024, on Feb. 4, 2025, after the closing bell.</li>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) dipped 39.7% to $2.35 in pre-market trading after the company priced $5 million public offering of 1.67 million common stock &amp; warrants at $3.00/share.</li>
<li>Stabilis Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) shares fell 19.7% to $6.00 in pre-market trading.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) fell 19.1% to $0.3202 in today's pre-market trading.</li>
<li>Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) shares dipped 18.7% to $3.21 in pre-market trading. Benson Hill shares jumped 119% on Thursday after the company announced results from a controlled broiler feeding trial conducted with Tyson Foods.</li>
<li>American Strategic Investment Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) shares tumbled 17.8% to $8.01 in pre-market trading.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) fell 15.1% to $189.32 in pre-market trading after the company reported third-quarter results.</li>
<li>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) fell 10.4% to $10.28 in pre-market trading after the company suspended its quarterly dividend.</li>
<li>Beazer Homes USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>) declined 8.6% to $25.33 in pre-market trading following worse-than-expected reported first-quarter financial results.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) fell 8.4% to $29.44 in pre-market trading following fourth-quarter earnings results.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/25/01/43335398/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a></li>
</ul>

Movers

AAPL

AVNW

BHIL

CIFR

CYCN

DECK

DGNX

ENVB

EVTV

KITT

KLTO

ORKT

SLNG

TDTH

TEAM

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

On Thursday, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) launched its RTX 5090 and 5080 graphics cards, only to see them sell out almost immediately.
What Happened: The highly anticipated Nvidia Series 5000 GPUs sold out rapidly, leaving many gamers frustrated, <a href="https://in.ign.com/nvidia-rtx-5080/223698/news/nvidia-rtx-5090-and-5080-sell-out-instantly-and-scalpers-are-already-cashing-in-with-6000-ebay-listi">reported</a> IGN. The GPUs were anticipated to have limited availability, a fact Nvidia had previously warned about.
Despite the warning, eager buyers lined up at <a href="https://www.benzinga.com/tech/25/01/43242360/jensen-huang-mania-mirrors-taylor-swift-people-are-camping-outside-retailers-for-nvidia-5000-series-gpus">U.S. distributor Micro Center</a>, hoping to secure one of the coveted cards.
However, the limited stock led to scalpers listing the RTX 5090 on eBay for over $6,000, a significant markup from its $1,999 MSRP, the report noted.
See Also: <a href="https://www.benzinga.com/markets/25/01/43377131/tim-cook-wont-say-how-apple-plans-to-handle-trumps-tariff-policies-but-heres-whats-at-stake-for-the-iphone-maker">Tim Cook Won&#8217;t Say How Apple Plans To Handle Trump&#8217;s Tariff Policies — But Here&#8217;s What&#8217;s At Stake For The iPhone Maker</a>
Third-party manufacturers also increased prices, with the Asus ROG Astral model reaching $2,799.
As a result, gamers expressed their frustration online, with some calling it a &#8220;paper launch&#8221; due to the lack of available stock.
Why It Matters: The scarcity of these GPUs is partly due to a design flaw in Nvidia&#8217;s Blackwell-based processors. This flaw affected production yields, impacting the availability of the RTX 5090 and 5080.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Nvidia&#8217;s focus on data center chips, which share the same manufacturing process, further strained consumer GPU production, the report stated.
Nvidia is expected to report its fourth-quarter earnings on Feb. 26. Last quarter, it posted a <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">revenue of $35.1 billion</a>, marking a 94% year-over-year surge and surpassing Wall Street's consensus estimate of $33.12 billion.
Price Action: Nvidia&#8217;s stock dipped 1.16% in pre-market trading to $123.20 on Friday after closing at $124.65 up 0.77% during regular hours on Thursday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43221770/apples-ipad-turns-15-today-heres-a-throwback-to-when-steve-jobs-explained-called-it-the-third-category-after-phones-and-notebooks" target="_blank" rel="noreferrer noopener">Apple's iPad Turns 15 Today: Here's A Throwback To When Steve Jobs Explained Called It The ‘Third Category' After Phones And Notebooks</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Media

NVDA

Nvidia RTX 5090 And 5080 Sell Out Instantly — Scalpers Jack Up Prices To $6,000 As Gamers Face 'Paper Launch' Frustration

Macro Economic Events

Econ #s

Economics

Germany Unemployment Rate For January 6.2% Vs. 6.2% Est.; 6.1% Prior

Germany Unemployment Change For January 11K Vs. 14K Est.; 10K Prior

Stifel analyst J. Bruce Chan upgrades C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) from Hold to Buy and maintains the price target from $113 to $113.

CHRW

Stifel Upgrades C.H. Robinson Worldwide to Buy, Maintains Price Target to $113

Former Department of Government Efficiency (DOGE) co-leader Vivek Ramaswamy has clarified his departure from the organization, emphasizing a strategic pivot toward elected office while <a href="https://www.benzinga.com/news/25/01/43078027/vivek-ramaswamy-expected-to-exit-trumps-doge-task-force-amid-ohio-governor-bid-report">addressing speculation about his relationship</a> with Tesla Inc. CEO Elon Musk.
What Happened: Speaking on the Flagrant podcast, Ramaswamy detailed his evolving approach to government reform. &#8220;If you want to save a lot of money, you got to do it through legislation,&#8221; Ramaswamy said, highlighting his focus on legal and constitutional issues.
The entrepreneur-turned-politician defended his exit, which had sparked rumors of tension with Musk, by explaining the natural divergence in their approaches. While Musk continues to lead DOGE&#8217;s technology-centric strategy, Ramaswamy expressed his intention to pursue reform through elected office, particularly at the state level.
During the interview, Ramaswamy criticized the current regulatory landscape, pointing to unelected bureaucrats&#8217; outsized influence on policy. &#8220;Most of the laws that decide what you can and can&#8217;t do in your life were actually never passed by Congress,&#8221; he noted, citing examples ranging from fishing licenses to nuclear plant permissions.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Vivek: Kicked out of DOGE? Elon Beef? Trump Relationship and More" width="500" height="281" src="https://www.youtube.com/embed/6dOfkRLWD7M?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
See Also: <a href="https://www.benzinga.com/government/regulations/25/01/43377987/after-imposing-tariffs-on-canada-donald-trump-threatens-100-levy-on-brics-for-move-against-dollar-how-will-us-manage-production-from-slippers-to-ships-asks-expert">After Imposing Tariffs On Canada, Donald Trump Threatens 100% Levy On BRICS For Move Against Dollar: &#8216;How Will US Manage Production From Slippers To Ships?,&#8217; Asks Expert</a>
Why It Matters: While stopping short of a formal announcement, Ramaswamy indicated his political aspirations would be revealed &#8220;in the next couple of weeks.&#8221; His comments particularly highlighted the governor&#8217;s role in driving executive action, suggesting a potential bid for Ohio&#8217;s governorship.
The transition marks a significant shift for Ramaswamy, who sees state-level executive positions as crucial leverage points for implementing meaningful government reform. His focus appears to be on addressing both federal and state-level regulatory challenges through elected office rather than through organizational reform efforts.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43377455/trumps-tariffs-could-force-us-to-buy-venezuelan-oil-theres-no-other-option-on-the-table-says-canadas-foreign-minister">Trump&#8217;s Tariffs Could Force US To Buy Venezuelan Oil: &#8216;There&#8217;s No Other Option On The Table,&#8217; Says Canada&#8217;s Foreign Minister Melanie Joly</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Social Media

Vivek Ramaswamy Clarifies DOGE Exit Amid Speculation Of Sour Ties To Elon Musk, Shifts Focus To Ohio Governorship Bid: 'You Have to Do It Through Legislation'

NIO Says Has Completed Its Previously Announced Repurchase Right Offer Relating To Its 0.50% Convertible Senior Notes Due 2027

Goldman Sachs analyst Michael Ng maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Buy and lowers the price target from $50 to $44.

CMCSA

Goldman Sachs Maintains Buy on Comcast, Lowers Price Target to $44

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has marked the option for white interiors as sold out on its launch series of the refreshed <a href="https://www.benzinga.com/tech/25/01/43221344/tesla-model-y-pricing-evolution-cuts-hikes-refreshes-over-two-years">Model Y vehicle</a> in the U.S., even before deliveries have commenced. 
What Happened: Tesla launched the refreshed Model Y in the U.S.<a href="https://www.benzinga.com/tech/25/01/43183608/tesla-launches-refreshed-model-y-in-us-with-25-price-hike-full-self-driving-included"> earlier this month</a>. Deliveries of the launch series of the long-range all-wheel drive variant of the refreshed vehicle, priced at $59,990, are slated to start in March. 
Launch series refers to a limited edition of the vehicle with exclusive badging and more that the company intends to make to celebrate the start of production. 
However, the option for customizing the Launch series vehicle with white interiors is already marked as sold out on Tesla&#8217;s U.S. website. Customers now have only the option to opt for an all-black five-seat interior. 
As for exterior paint options, the company has listed just quicksilver, ultra red, pearl white multi-coat, and stealth grey in the U.S. In China, however, the company has also listed an option for glacier blue exterior paint on the vehicle. 
Why It Matters: Tesla CEO Elon Musk&nbsp;said on Wednesday that all of the company's many factories will start producing the new Model Y vehicle starting in February but will <a href="https://www.benzinga.com/25/01/43328898/elon-musk-warns-teslas-new-model-y-will-result-in-several-weeks-of-lost-production-for-ev-giant-in-q1">lose production in the days of retooling factory.</a>
The CEO also warned that margins will be impacted due to idle capacity and other ramp-related costs. However, these challenges will be overcome once production is ramped, he said.
While in the U.S., the refreshed vehicle is listed alongside older versions of the vehicle, in China, it replaced the older version. In both geographies, deliveries are slated to start in March.
Model Y is manufactured at Tesla's factory in California, as well as its gigafactories in Shanghai, Berlin, and Texas. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43375903/tesla-researcher-estimates-drop-in-ev-deliveries-for-2025-despite-promise-of-new-models">Tesla Researcher Predicts Drop In Deliveries For Elon Musk&#8217;s EV Giant In 2025 Despite New Model Launches</a></li>
<li></li>
</ul>
Image via Tesla

Tesla Marks White Interiors On Launch Series Of Refreshed Model Y As Sold Out Before Deliveries Begin

Insider trades: Walmart, Teva among notable names this week

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals (IONS – Research Report) and...

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Anteris Technologies Global Corp. (AVR)

Ionis Pharmaceuticals (IONS) announced highlights from the company's 2024 achievements and previewed important milestones expected in 2025. The hig...

Ionis unveils pipeline plan for 2025, expects 4 independent product launches

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), retaining the price target of $55...

Ionis Pharmaceuticals: Hold Rating Amid Uncertainty in Future Financial Performance

Ionis Pharmaceuticals (IONS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Ionis Pharmaceuticals: Strategic Path to Cash Flow Positivity and Strong Pipeline Drive Buy Rating

David Lebowitz, an analyst from Citi, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target rema...

Ionis Pharmaceuticals: Promising Pipeline and Strategic Shifts Drive Buy Rating

RBC Capital analyst Luca Issi reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $70.00. The...

RBC Capital Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...

Ionis Pharmaceuticals: Strong Pipeline and Market Potential Drive 'Buy' Rating

Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis

Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential

AZNCF

BIIB

TEVA

Press Releases

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

Ionis reports third quarter 2024 financial results

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis to present at upcoming investor conferences

Health Care

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

PRAX

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ADMA Biologics

Akero Therapeutics

Alkermes

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

RBC Capital

Needham

Piper Sandler

Wells Fargo

Guggenheim

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob" target="_blank" rel="noopener" data-google-interstitial="false">혁신 분야</a>에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다.
이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.
아크 이노베이션: 우드와 <a href="https://www.benzinga.com/topic/ark-funds">아크 펀드</a>는 Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 2014년 10월 31일에 출시했다. 이 펀드는 이 회사의 가장 유명하고 가장 큰 펀드로 성장했으며, 현재 57억 8천만 달러의 운용 자산을 보유하고 있다.
&#8220;ARRK는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 국내 및 해외 주식에 주로 투자하여 펀드의 투자 테마인 파괴적 혁신(disruptive innovation)와 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkk">웹사이트</a>에서 설명한다.
파괴적 혁신 테마에는 자율 이동성, 정밀 치료, 차세대 클라우드, 신경망, 지능형 기기, 디지털 지갑, 디지털 자산, 스마트 계약 및 멀티오믹 기술이 포함된다.
&#8220;ARK는 &#8216;파괴적 혁신&#8217;을 세상이 돌아가는 방식에 잠재적으로 도전할 수 있는 기술적으로 구현된 새로운 제품이나 서비스의 도입으로 정의한다.&#8221;
현재 ARKK ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>로블록스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>로빈후드 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>블록 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>크리스퍼 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>유아이패스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 161.4% 상승했다. 이 수익률은 S&amp;P 500을 추적하는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 현재 10년 수익률에는 미치지 못한다.
아래의 표는 ARKK의 수익률이 SPY와 어떻게 비교되는지를 보여준다. SPY는 <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-ETF-hits-milestone-as-all-time-highs-conti">가장 오래되고 가장 큰</a> 미국 ETF이다:
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>+19.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>+2.6%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKK 설립 이래 2014년 10월 31일 기준</td>
<td>+10.2%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
아래의 차트는 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a>에서 제공한 ARKK의 10년 수익률을 보여준다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" sizes="(max-width: 1003px) 100vw, 1003px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" alt="" width="1003" height="513" /></a></figure>
비교를 위해 SPY의 10년 차트도 보여드리겠다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" alt="" width="995" height="508" /></a></figure>
다음 읽어보기: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">독점: 캐시 우드가 테슬라가 기술 주식으로 거래되어야 하는 이유를 Benzinga에 말했다.</a>
아크 지노믹스: Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 2014년 10월 31일에 아크 펀드에 의해 출시되었다. 현재 이 ETF 펀드는 13억 3천만 달러의 자산을 운용하고 있다.
&#8220;ARKG는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 헬스 케어, 정보 기술, 소재, 에너지 및 소비재 등 여러 섹터의 국내외 주식에 주로 투자하며, 펀드의 투자 테마인 유전체 혁명(genomics revolution)과 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkg">웹사이트</a>에서 설명한다.
이 유전체 혁명 ETF의 테마에는 정밀 치료, 멀티오믹 기술, 프로그래머블 생물학, 신경망, 차세대 클라우드 및 적응형 로보틱스가 포함된다.
현재 ARKG ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>트위스트 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>리커젼 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>크리스퍼 테라퓨틱스: 7.0%</li>
<li>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>아이오니스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>누릭스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>나테라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x 지노믹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 38.9% 상승했다. 이 수익률은 현재 SPDR S&amp;P 500 ETF Trust의 10년 수익률에는 미치지 못한다.
ARKG의 수익률이 SPY와 어떻게 비교되는지를 살펴보겠다.
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>-7.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-29.9%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>-1.9%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKG 설립 이래 2014년 10월 31일 기준</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
다음은 ARKG의 10년 차트다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" alt="" width="993" height="510" /></a></figure>
중요성 (Why It&#8217;s Important): 위의 차트들은 ARKK와 ARKG가 모두 투자자들에게 몇 년 동안 강력한 성장과 수익률을 경험했지만, 최근 몇 년 동안은 더 넓은 S&amp;P 500 시장 지수를 하회한 것을 보여준다.
한때 이 ETF들은 가장 화제가 된 펀드들 중 하나였으며, 이 회사의 일일 거래 활동은 종종 주식을 상승시켰다. 이는 우드의 뛰어난 성과 덕분이다.
S&amp;P 500 ETF는 분기마다 리밸런싱을 하지만, 이 액티브하게 관리되는 펀드는 거의 매일 거래를 완료한다. 종종 주가가 상승하는 주식의 평균 매입가가 시간이 지남에 따라 상승하여 수익률에 부정적인 영향을 미칠 수 있다.
아크 펀드는 일반적으로 향후 5년에서 10년 동안 강력한 성장을 할 것으로 믿는 회사들에 투자한다. 이는 펀드의 수익률이 때때로 몇 년이 걸려야 나타날 수 있음을 의미한다.
우드는 엔비디아의 주식을 2014년에 약 5달러에 매수한 것과 같이 많은 테마에 대해 일찍 투자한 바 있다. 이는 가장 최근의 주식 분할 이전의 일이었다. 이 펀드는 나중에 2022년 말과 2023년 초에 이 포지션에서 완전히 매도하여 지난 2년 가까이 <a style="font-size: revert;" href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early">엄청난 수익을 놓쳤</a>다.
이 펀드 매니저는 또한 테슬라 성장 스토리에 일찍 투자했다. 2018년 2월에 이 전기차 회사에 대해 $4,000 목표 주가를 <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">예측</a>했다. 당시에는 가격 예측으로 비웃음거리가 되었지만, 주가는 2021년 1월에 분할 기준으로 목표 주가에 도달했다.
테슬라에 대한 예측이 맞아들어간 것은 우드의 펀드 매니저로서의 위상을 높이는 데 도움이 되었고, 아크 펀드 ETF들에 대한 관심이 증가하는 계기가 되었다.
최근 몇 년 동안 아크 펀드 ETF들에 대한 관심이 식었지만, 많은 투자자들은 여전히 그들의 영향을 기억하고 일일 거래 활동을 계속 추적하며, 우드가 향후 5년에서 10년 동안 보유할 주식을 주의 깊게 지켜보고 있다.

다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">독점: 캐시 우드는 왜 비트코인이 100만 달러에 이를 것이라고 생각하는가? 그녀는 무엇을 알고 있기에?</a></li>
</ul>
이미지 제공: Ark Invest 및 Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Ionis Pharmaceuticals

뉴스

에 대한 최신 뉴스 Ionis Pharmaceuticals (NASDAQ:IONS) 주식

금요일, 11월 01, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌